Iron deficiency in patients with cancer: a prospective cross-sectional study.

cancer metabolic disorders

Journal

BMJ supportive & palliative care

ISSN: 2045-4368

Titre abrégé: BMJ Support Palliat Care

Pays: England

ID NLM: 101565123

Informations de publication

Date de publication:
30 Jul 2021

Historique:

received: 07 04 2021

accepted: 30 06 2021

entrez: 31 7 2021

pubmed: 1 8 2021

medline: 1 8 2021

Statut: aheadofprint

Résumé

Despite the deleterious consequences of iron deficiency (ID) in patients with cancer, underdiagnosis is frequent. The CARENFER study aimed to assess the prevalence of ID using both serum ferritin concentration and transferrin coefficient saturation (iron-saturation of transferrin, TSAT) index, as well as ID anaemia in patients with cancer. This prospective cross-sectional study was conducted in 15 oncology units in France in 2019. All patients present in the medical unit during the 2-week study period, regardless of the type of tumour (solid or haematological) and treatment, were eligible. Serum ferritin concentration, TSAT index and haemoglobin level were determined. ID and ID-associated anaemia were defined according to European Society of Medical Oncology 2018 Guidelines: ID was defined either as ferritin <100 µg/L (absolute ID) or as ferritin ≥100 µg/L and TSAT <20% (functional ID). A total of 1221 patients with different types of solid malignant tumours were analysed: median age 64 years; 89.4% under treatment for their cancer, mainly by chemotherapy (75.4%). Overall, ID was found in 57.9% (55.1-60.6) of patients. Among them, functional ID accounted for 64% of cases. ID anaemia was reported in 21.8% (19.6-24.2) of all patients with cancer. ID was highly prevalent in untreated (75/130, 57.4%) and non-anaemic (419/775, 54.1%) patients. This study highlights the high prevalence of ID in patients with cancer, whether or not associated with anaemia or treatment. These results emphasise the need to a better detection and management of ID in cancer, thereby optimising overall patient care. ClinicalTrials.gov Identifier: NCT03924271.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

This prospective cross-sectional study was conducted in 15 oncology units in France in 2019. All patients present in the medical unit during the 2-week study period, regardless of the type of tumour (solid or haematological) and treatment, were eligible. Serum ferritin concentration, TSAT index and haemoglobin level were determined. ID and ID-associated anaemia were defined according to European Society of Medical Oncology 2018 Guidelines: ID was defined either as ferritin <100 µg/L (absolute ID) or as ferritin ≥100 µg/L and TSAT <20% (functional ID).

RESULTS RESULTS

A total of 1221 patients with different types of solid malignant tumours were analysed: median age 64 years; 89.4% under treatment for their cancer, mainly by chemotherapy (75.4%). Overall, ID was found in 57.9% (55.1-60.6) of patients. Among them, functional ID accounted for 64% of cases. ID anaemia was reported in 21.8% (19.6-24.2) of all patients with cancer. ID was highly prevalent in untreated (75/130, 57.4%) and non-anaemic (419/775, 54.1%) patients.

CONCLUSION CONCLUSIONS

This study highlights the high prevalence of ID in patients with cancer, whether or not associated with anaemia or treatment. These results emphasise the need to a better detection and management of ID in cancer, thereby optimising overall patient care.

TRIAL REGISTRATION NUMBER BACKGROUND

ClinicalTrials.gov Identifier: NCT03924271.

Identifiants

DOI: 10.1136/bmjspcare-2021-002913 PMID: 34330792

pubmed: 34330792

pii: bmjspcare-2021-002913

doi: 10.1136/bmjspcare-2021-002913

pii:

doi:

Banques de données

ClinicalTrials.gov

['NCT03924271']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Investigateurs

Valérie Andrieu (V)

Gilles Berrut (G)

Patrice Cacoub (P)

Aurélien Carnot (A)

Bruno Chauffert (B)

Gabriel Choukroun (G)

Alain Cohen-Solal (A)

Nadim Fares (N)

Elisabeth Luporsi (E)

Anthony Lopez (A)

Vincent Massard (V)

Sophie Morin (S)

Gaël Nicolas (G)

Katell Peoc'h (K)

Alain Pesce (A)

Laurent Peyrin-Biroulet (L)

Anne-Marie Ruppert (AM)

Nacera Sakek (N)

Hélène Simon (H)

Achille Tchalla (A)

Anthony Turpin (A)

Jean-Marc Tourani (JM)

Jean-Noël Trochu (JN)

Informations de copyright

Déclaration de conflit d'intérêts

Competing interests: PC, EL, V. Andrieu, G. Choukroun, A. Cohen-Solal, G. Nicolas, K. Peoc’h, L. Peyrin-Biroulet, J-N. Trochu and A. Lopez received consultancies and honoraria from Vifor Pharma.